Product Description
Levetiracetam is used alone and along with other medications to control partial-onset seizures (seizures that involve only one part of the brain) in adults, children, and infants 1 month of age or older. Levetiracetam is also used in combination with other medications to treat seizure in adults and children 12 years of age or older with juvenile myoclonic epilepsy. Levetiracetam is also used in combination with other medications to treat primary generalized tonic-clonic seizures (formerly known as a grand mal seizure; seizure that involves the entire body) in adults and children 6 years of age or older with epilepsy. Levetiracetam is in a class of medications called anticonvulsants. It works by decreasing abnormal excitement in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a699059.html)
Mechanisms of Action: SV2A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Epilepsy | Epilepsy, Generalized | Epilepsy, Tonic-Clonic | Myoclonic Epilepsy, Juvenile | Seizures | Epilepsy | Epilepsy, Generalized | Myoclonic Epilepsy, Juvenile | Seizures | Epilepsy | Epilepsy, Generalized | Myoclonic Epilepsy, Juvenile | Seizures
Known Adverse Events: Depressive Disorder | Dizziness | Asthenia
Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan, United Kingdom, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Epilepsy|Epilepsy, Generalized|Epilepsy, Tonic-Clonic|Seizures
Phase 2: Alzheimer Disease|Cognitive Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AGB101 NE4 | P2 |
Recruiting |
Alzheimer Disease|Cognitive Dysfunction |
2028-07-01 |
|
| PEACH | P3 |
Active, not recruiting |
Seizures |
2027-01-27 |
|
| jRCT2080223815 | P3 |
Completed |
Epilepsy |
2024-03-31 |
|
| JapicCTI-183871 | P3 |
Active |
Epilepsy |
2022-03-31 |